Variables | Log-odds | SE | z | P>|z| | (95% CI) |
---|---|---|---|---|---|
Constant | 1.817 | 1.128 | 1.610 | 0.107 | −0.394 to 4.027 |
Main effects | |||||
LPCR_0 (centred) | −0.166 | 0.020 | −8.160 | 0.000 | −0.205 to −0.126 |
Treatment, ETV | 1.429 | 0.214 | 6.680 | 0.000 | 1.010 to 1.848 |
HBeAg (positive) | −1.414 | 0.572 | −2.470 | 0.013 | −2.536 to −0.293 |
Time (centred at 48 weeks) | 0.025 | 0.005 | 5.290 | 0.000 | 0.016 to 0.035 |
Clinical study (ID=27) | −0.450 | 0.563 | −0.800 | 0.424 | −1.553 to 0.653 |
Interaction terms | |||||
ETV * Time (centered at 48 weeks) | 0.035 | 0.007 | 4.710 | 0.000 | 0.020 to 0.049 |
ETV *PCR (centered at 48 weeks) | −0.049 | 0.029 | −1.660 | 0.096 | −0.106 to 0.009 |
ETV * HBeAg (positive) | 0.264 | 0.244 | 1.080 | 0.278 | −0.213 to 0.742 |
ETV, entecavir; LPCR_0, natural log of baseline HBV DNA measured by PCR assay.